1
|
Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Tapia C, Ileana-Dumbrava E, Janku F, Meric-Bernstam F. Abstract P6-21-04: Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-21-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: PTEN functions as a negative regulator of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway to promote balanced cell proliferation, survival and differentiation. PTEN loss occurs across a variety of cancer subtypes; PTEN-deficient tumors are dependent on PI3Kβ activity, making PI3Kβ a compelling target. We evaluated the efficacy of PI3Kβ inhibitor AZD8186 as a single agent and in combination with standard chemotherapy and immune checkpoint inhibitors focused on tumors with loss of PTEN function.
Methods: In vitro, cell proliferation assays were performed to determine the half maximal inhibitory concentration (IC50) after 3 days of treatment and to test the effects in combination with standard chemotherapy. Colony formation assays were performed to confirm efficacy of AZD8186 in PTEN-deficient cell lines. Western blot analysis was performed to assess PTEN protein expression and to evaluate effects of AZD8186 on PI3K signaling. In vivo, antitumor efficacy of AZD8186 as a single agent as well as in combination with paclitaxel and anti-PD1 was evaluated.
Results: AZD8186 inhibited the cell proliferation of three of ten TNBC cell lines in vitro; PTEN loss was significantly correlated with AZD8186 sensitivity (p= 0.008). Colony formation assay confirmed sensitivity of PTEN-deficient cell lines to AZD8186. AZD8186 inhibited PI3K signaling with decreased expression of pAKT, pGSK3β, pPRAS40 and pS6. AZD8186 treatment of PTEN-deficient cell lines, MDA-MB-436 and MDA-MB-468, resulted in increased apoptosis. Cell proliferation assays demonstrated additive effect of the combination of paclitaxel with AZD8186. AZD8186 significantly enhanced antitumor activity of paclitaxel in MDA-MB-436 and MDA-MB-468 cell-line-derived xenografts, with disease stabilization in the latter. In syngeneic models, AZD8186 enhanced antitumor efficacy of anti-PD1 antibodies in PTEN-deficient BP murine melanoma xenograft (p=0.0073), but not in PTEN-wildtype colon carcinoma, CT26.
Conclusion: AZD8186 has single agent efficacy in PTEN-deficient triple negative breast cancer cell lines in vitro, with modest single agent efficacy in vivo. AZD8186 enhanced the antitumor efficacy of paclitaxel and of Anti-PD1 antibodies in vivo. Further study is needed to determine optimal combination therapies for PTEN-deficient solid tumors.
Citation Format: Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Tapia C, Ileana-Dumbrava E, Janku F, Meric-Bernstam F. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-21-04.
Collapse
Affiliation(s)
| | - M Zhao
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - A Akcakanat
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - KW Evans
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - E Yuca
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - C Tapia
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - F Janku
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
2
|
Owusu-Brackett N, Scott S, Yuca E, Evans KW, Tapia C, Meric-Bernstam F. Abstract P1-13-04: Efficacy of adjuvant 5-Fluorouracil in residual HER2-negative breast cancer following neoadjuvant chemotherapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-13-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Patients with residual disease following neoadjuvant chemotherapy have an increased risk of relapse. Recently the CREATE-X trial demonstrated that adjuvant capecitabine (oral prodrug of 5'deoxy-5-fluorouridine), prolonged disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease after neoadjuvant chemotherapy containing anthracycline, taxane, or both. Therefore, we sought to evaluate the antitumor efficacy of 5-fluorouracil (5-FU) in patient-derived xenografts (PDXs) from residual tumors resistant to neoadjuvant chemotherapy.
Methods: Antitumor efficacy of 5-FU was assessed in vivo in three PDXs varying in hormone receptor status (0, 4% and 11% respectively), generated from residual tumors of primary breast cancer patients treated with neoadjuvant chemotherapy containing anthracycline, and taxanes. In addition, significance of timing of therapy was also assessed, comparing efficacy of initiating treatment upon implantation (immediate start cohort; mimicking treating residual disease with adjuvant therapy), with initiating treatment upon establishment of PDX (standard start cohort).
Results: 5-FU was efficacious in established PDX models that are triple negative (0% ER; p< 0.0001), low ER positive (4% ER, p=0.0213) and ER-positive (11% ER; p= 0.0390), decreasing growth compared to the cohort. However, there was no statistically significant difference between the immediate start cohort and standard start cohort. Western blot analysis of the treatment-naïve derived mouse tumors recognized RB as a predictive biomarker for 5-FU response.
Conclusion: 5-FU has anti-tumor activity in residual HER2-negative PDX models resistant to taxanes, and anthracyclines in the neoadjuvant setting.
Citation Format: Owusu-Brackett N, Scott S, Yuca E, Evans KW, Tapia C, Meric-Bernstam F. Efficacy of adjuvant 5-Fluorouracil in residual HER2-negative breast cancer following neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-13-04.
Collapse
Affiliation(s)
| | - S Scott
- MD Anderson Cancer Center, Houston, TX
| | - E Yuca
- MD Anderson Cancer Center, Houston, TX
| | - KW Evans
- MD Anderson Cancer Center, Houston, TX
| | - C Tapia
- MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
3
|
Pairawan SS, Yuca E, Evans K, Annis A, Narasimhan N, Sutton D, Carvajal LA, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Illeana Dumbrava EE, Aivado M, Meric-Bernstam F. Abstract P6-20-11: The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-20-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: MDMX and MDM2 are endogenous inhibitors of the p53 tumor suppressor protein. MDMX levels are frequently elevated in luminal breast cancer, which generally expresses wild-type p53. ALRN-6924, an α-helical stapled peptide, is the first and only dual inhibitor of MDMX and MDM2 currently in clinical trials for solid tumors and hematological malignancies. We sought to determine the antitumor efficacy of the combination of ALRN-6924 with taxanes in models of human breast cancer.
Methods: Sulforhodamine B colorimetric assay was used to assess the cytotoxicity of the combination of ALRN-6924 with taxanes in vitro. Athymic nude mice were implanted with MCF-7 tumors and treated for four weeks with ALRN-6924 alone and in combination with paclitaxel in cremaphor (Taxol®, study #1) or a nanoparticle-albumin-bound (nab) formulation (Abraxane®, study #2). In study #1, ALRN-6924 (5, 10 mg/kg) was dosed twice weekly and paclitaxel (10, 15 mg/kg) was dosed weekly, with paclitaxel administered 6 h prior to ALRN-6924. In study #2, ALRN-6924 alone (5 mg/kg) was dosed twice weekly while nab-paclitaxel (15 mg/kg) was administered weekly in combination at -24h, -6h, 0h, +6h, or +24h relative to ALRN-6924 administration.
Results: ALRN-6924 was found to have synergistic activity with paclitaxel in both MCF-7 and ZR-75-1 cell lines in vitro (Combination index: 0.874 and 0.323 respectively). In in vivo study #1, the combination of ALRN-6924 and paclitaxel significantly inhibited MCF-7 tumor growth compared to either agent alone (p<0.005). Paclitaxel 15 mg/kg + ALRN-6924 5 mg/kg resulted in the greatest tumor inhibition with average tumor size decreased by 13% at four weeks versus the starting size.
In study #2, the combination of nab-paclitaxel with ALRN-6924 administered -6h to +24h relative to nab-paclitaxel resulted in improved efficacy over either single agent and a significant increase in the number of tumor regressions (up to 6/10 with 3 consecutive measurements <50% of starting volume) compared to nab-paclitaxel alone (1/10, p<0.005). When ALRN-6924 was administered 24h prior to nab-paclitaxel, there was a marked decrease in efficacy and no tumor regressions were observed.
In both studies, drug treatments were well tolerated with no significant weight loss in mice.
Conclusion: The significant increase in efficacy observed with ALRN-6924 in combination with paclitaxel supports further evaluation in patients with breast cancer.
Citation Format: Pairawan SS, Yuca E, Evans K, Annis A, Narasimhan N, Sutton D, Carvajal LA, Ren J-G, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Illeana Dumbrava EE, Aivado M, Meric-Bernstam F. The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-20-11.
Collapse
Affiliation(s)
- SS Pairawan
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - E Yuca
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - K Evans
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - A Annis
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - N Narasimhan
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - D Sutton
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - LA Carvajal
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - J-G Ren
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - S Santiago
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - V Guerlavais
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - A Akcakanat
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - C Tapia
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - EE Illeana Dumbrava
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - M Aivado
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| | - F Meric-Bernstam
- The University of Texas MD Anderson Cancer Center, Houston, TX; Aileron Therapeutics, Cambridge, MA
| |
Collapse
|
4
|
Paez Arango N, Evans KW, Zhao M, Yuca E, Scott SM, Janku F, Ueno NT, Tripathy D, Kim C, Naing A, Funda MB. Abstract P3-07-01: Selinexor, a selective inhibitor of nuclear export, demonstrates efficacy in preclinical models of triple negative breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-07-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Approximately 15% of all breast cancers are categorized as triple negative (TNBC) for which the only chemotherapy is known to be effective, yet often fails to achieve remission. Nuclear exporter XPO1 (Exportin1 or CRM1) is a promising target for cancer therapy that mediates the transport of multiple tumor suppressors and cell cycle regulators that have been known to be relevant predictors in the mechanism and severity of TNBC. Given the pressing need for novel therapies for this disease, we sought to determine the antitumor effects of selinexor, a novel inhibitor of nuclear export, on triple negative breast cancers in vitro and in vivo as well as to address its mechanism of action.
Methods: 26 breast cancer cell lines of different breast cancer subtypes were treated with selinexor in vitro. Using cell proliferation assays the half maximal inhibitory concentration (IC50) was calculated using isobologram curves after 3 days of treatment; sensitivity was defined as IC50 <1000nM. We then assessed mechanistic effects on apoptosis and cell proliferation using flow cytometry analysis with annexin V and propidium iodide and using western blot analysis we also studied its effects on markers of inhibition of apoptosis. In vivo efficacy was studied as single agent and in combination with standard chemotherapy agents in TNBC patient derived xenografts (PDXs) with varying levels of sensitivity to chemotherapy as well as with varying statuses of TP53 and PIK3CA, and gene expression subtypes.
Results: Selinexor demonstrated growth inhibition in all fourteen TNBC cell lines tested; TNBC cell lines were more sensitive to selinexor (median IC50 44nM, range 11 - 550nM), compared to ER+ cells lines (median IC50 of 13000 nM, range of 40nM - > 1000 nM; P=0.017). Treatment with selinexor decreased expression levels of XPO1, as well as survivin and XIAP, and induced apoptosis. In multiple TNBC cell lines selinexor was synergistic with paclitaxel, carboplatin, eribulin and doxorubicin in vitro (median combination index 0.6, range 0.5-0.8). Selinexor as a single agent reduced tumor growth in vivo in 4 of 5 different TNBC PDX models with a median tumor growth inhibition ratio score (T/C) of 48% (range 34-59%) and demonstrated greater antitumor efficacy in combination with paclitaxel or eribulin with an average T/C score of 27% and 12% respectively.
Conclusions: Selinexor is a promising therapeutic agent for triple negative breast cancer and it has potential as a combination agent with standard chemotherapy.
Citation Format: Paez Arango N, Evans KW, Zhao M, Yuca E, Scott SM, Janku F, Ueno NT, Tripathy D, Kim C, Naing A, Funda M-B. Selinexor, a selective inhibitor of nuclear export, demonstrates efficacy in preclinical models of triple negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-07-01.
Collapse
Affiliation(s)
| | - KW Evans
- MD Anderson Cancer Center, Houston, TX
| | - M Zhao
- MD Anderson Cancer Center, Houston, TX
| | - E Yuca
- MD Anderson Cancer Center, Houston, TX
| | - SM Scott
- MD Anderson Cancer Center, Houston, TX
| | - F Janku
- MD Anderson Cancer Center, Houston, TX
| | - NT Ueno
- MD Anderson Cancer Center, Houston, TX
| | | | - C Kim
- MD Anderson Cancer Center, Houston, TX
| | - A Naing
- MD Anderson Cancer Center, Houston, TX
| | - M-B Funda
- MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
5
|
Hnilova M, Liu X, Yuca E, Jia C, Wilson B, Karatas AY, Gresswell C, Ohuchi F, Kitamura K, Tamerler C. Multifunctional protein-enabled patterning on arrayed ferroelectric materials. ACS Appl Mater Interfaces 2012; 4:1865-71. [PMID: 22458431 DOI: 10.1021/am300177t] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
This study demonstrates a biological route to programming well-defined protein-inorganic interfaces with an arrayed geometry via modular peptide tag technology. To illustrate this concept, we designed a model multifunctional fusion protein, which simultaneously displays a maltose-binding protein (MBP), a green fluorescence protein (GFPuv) and an inorganic-binding peptide (AgBP2C). The fused combinatorially selected AgBP2C tag controls and site-directs the multifunctional fusion protein to immobilize on silver nanoparticle arrays that are fabricated on specific domain surfaces of ferroelectric LiNbO(3) via photochemical deposition and in situ synthesis. Our combined peptide-assisted biological and ferroelectric lithography approach offers modular design and versatility in tailoring surface reactivity for fabrication of nanoscale devices in environmentally benign conditions.
Collapse
|
6
|
Keskin BC, Yuca E, Ertekin O, Yüksel B, Memon AR. Expression characteristics of ARF1 and SAR1 during development and the de-etiolation process. Plant Biol (Stuttg) 2012; 14:24-32. [PMID: 21973219 DOI: 10.1111/j.1438-8677.2011.00482.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
ARF1 (ADP-ribosylation factor 1) and SAR1 (secretion-associated RAS super family) are involved in the formation and budding of vesicles throughout plant endomembrane systems. The molecular mechanisms of this transport have been studied extensively in mammalian and yeast cells. However, very little is known about the mechanisms of coat protein complex (COP) formation and recruitment of COP-vesicle cargoes in plants. To provide insights into vesicular trafficking in Pisum sativum L., we investigated mRNA and protein expression patterns of ARF1 and SAR1 in roots and shoots at early growth stages and in the de-etiolation process. We showed that ARF1 was concentrated mostly in the crude Golgi fractions, and SAR1 was concentrated predominantly in the crude ER fractions of de-etiolated shoots. ARF1 and SAR1 proteins were several times more abundant in shoots relative to roots. In total protein homogenates, the expression level of SAR1 and ARF1 was higher in shoots of dark-grown pea plants than light-grown plants. In contrast, ARF1 was higher in roots of light-grown pea relative to roots of dark-grown pea. With ageing, the ARF1 mRNA in roots was reduced, while SAR1 expression increased. Unlike ARF1 transcripts, ARF1 protein levels did not fluctuate significantly in root and shoot tissue during early development. The relative abundance of SAR1 protein in root tissues may suggest a high level of vesicular transport from the ER to the Golgi. Experimental results suggested that white light probably affects the regulation of ARF1 and SAR1 protein levels. On the other hand, short-term white light affects SAR1 but not ARF1.
Collapse
Affiliation(s)
- B Cevher Keskin
- Plant Molecular Biology Laboratory, TUBITAK, The Scientific and Technological Research Council of Turkey, Marmara Research Center, Genetic Engineering and Biotechnology Institute, Gebze, Kocaeli, Turkey.
| | | | | | | | | |
Collapse
|